| Jiang, Nan |
NCT06232395: Early Detection and Post-operative Monitoring of Gastric Cancer |
|
|
| Recruiting | N/A | 1197 | RoW | DNA test | SUZHOU HUHU HEALTH & TECHNOLOGY Inc.,, Fudan University | Gastric Cancer | 02/26 | 02/26 | | |
NCT04722796: HANGZHOU Solution in Bicuspid AS Undergoing TAVR |
|
|
| Recruiting | N/A | 508 | RoW | TAVR with Venus A plus using supra-annular sizing and THV implantation technique (Hangzhou solution), Hangzhou solution, TAVR with Venus A plus using annular sizing and THV implantation technique, Traditional sizing strategy (Annulus based sizing strategy) | Second Affiliated Hospital, School of Medicine, Zhejiang University, Venus MedTech (HangZhou) Inc., First Affiliated Hospital Bengbu Medical College, Chinese PLA General Hospital, Fujian Medical University Union Hospital, Xiamen University Affiliated Cardiovascular Hospital, Guangdong People's Hospital, Zhengzhou Cardiovascular Hospital, The First Affiliated Hospital of Zhengzhou University, Hennan Provincial Chest Hospital, Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Central South University, Northern Jiangsu Province People's Hospital, The First Affiliated Hospital of Nanchang University, Second Affiliated Hospital of Nanchang University, The Affiliated Hospital of Qingdao University, Shanxi cardiovascular hospital, Tianjin Chest Hospital, Ning Bo First Hospital | Aortic Stenosis, Aortic Stenosis With Bicuspid Valve | 04/24 | 04/28 | | |
FAVOR IV-QVAS, NCT03977129: Quantitative Flow Ratio (QFR) Guided Revascularization Strategy for Patients Undergoing Primary Valve Surgery With Comorbid Coronary Artery Disease |
|
|
| Active, not recruiting | N/A | 792 | RoW | QFR-guided strategy, CAG-guided strategy | Ruijin Hospital, Med-X Research Institute, Shanghai Jiao Tong University | Primary Valvular Heart Disease With Comorbid Coronary Artery Disease, Planned to Undergo Elective On-pump Valve Surgery Due to Primary Mitral and/or Aortic Valvular Heart Disease | 09/24 | 12/26 | | |
| Active, not recruiting | N/A | 150 | US | WeChat Quit Coach, Leaflet, Optional Nicotine Replacement Therapy (NRT) Patches or Lozenges, Habitrol, Nicorette | NYU Langone Health, Asian Americans for Equality, Chinese American Planning Council, National Institute on Minority Health and Health Disparities (NIMHD) | Smoking Cessation | 12/24 | 12/24 | | |
| liu, yin |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
Rainbow, NCT06341621: Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib |
|
|
| Recruiting | 3 | 1900 | RoW | 3-year abemaciclib without chemo, treatment of physician's choice | Fudan University | Breast Cancer | 02/27 | 01/29 | | |
| Recruiting | 3 | 808 | RoW | Epirubicin, CTX, Paclitaxel, ddEpirubicin, ddCTX, Paclitaxel(with carbo), Carboplatin | Fudan University | Triple-negative Breast Cancer | 06/24 | 06/25 | | |
NCT06355037: Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer |
|
|
| Recruiting | 2 | 10 | RoW | Quercetin, Dasatinib, Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum | Fudan University | Triple-negative Breast Cancer | 12/24 | 01/25 | | |
NCT05749588: FUSCC Refractory TNBC Platform Study (FUTURE2.0) |
|
|
| Recruiting | 2 | 120 | RoW | A1: SHR-A1811, A2: SHR-A1811 with Camrelizumab, SHR-1210, B1: TROP2 ADC, B2: TROP2 ADC with Camrelizumab, C1: SHR-A1811, C2: SHR-A1811 with BP102, D1: TROP2 ADC, D2: TROP2 ADC with BP102, E1: SHR-A1811, F1: TROP2 ADC, G1: SHR-A1811, H1: TROP2 ADC | Fudan University | Triple-negative Breast Cancer | | | | |
| Recruiting | N/A | 13000 | RoW | | Tianjin Chest Hospital | Myocardial Infarction, Acute | 01/23 | 12/23 | | |
NCT05862103: Long-Term Follow-Up in Patients With Acute Myocardial Infarction Cohort |
|
|
| Recruiting | N/A | 15000 | RoW | Treatment Strategies | Yu Bo | Acute Myocardial Infarction, Adverse Event | 08/25 | 12/26 | | |
| Li, Chunjie |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
| Recruiting | N/A | 4500 | RoW | | Harbin Medical University, Abbott | Acute Myocardial Infarction | 07/21 | 12/22 | | |
NCT05862103: Long-Term Follow-Up in Patients With Acute Myocardial Infarction Cohort |
|
|
| Recruiting | N/A | 15000 | RoW | Treatment Strategies | Yu Bo | Acute Myocardial Infarction, Adverse Event | 08/25 | 12/26 | | |
| Zhao, Zhijing |
NCT05862103: Long-Term Follow-Up in Patients With Acute Myocardial Infarction Cohort |
|
|
| Recruiting | N/A | 15000 | RoW | Treatment Strategies | Yu Bo | Acute Myocardial Infarction, Adverse Event | 08/25 | 12/26 | | |
| Cong, Hongliang |
| Completed | 3 | 226 | Europe, Canada, US, RoW | Bentracimab (PB2452) Infusion | SFJ Pharmaceuticals, Inc. | Hemorrhage, Urgent Surgery, Invasive Procedure | 09/24 | 09/24 | | |
| Completed | 2 | 225 | RoW | Qishen Yiqi dripping pills 2 bags/time + Qishen Yiqi dripping pills placebo 2 bags/time, Qishen Yiqi dripping pills 4 bags/time, Qishen Yiqi dripping pills placebo 4 bags/time | Tasly Pharmaceutical Group Co., Ltd | Chronic Heart Failure With Preserved Ejection Fraction | 12/24 | 12/24 | | |
NCT04569669: The Sensitivity and Specificity of CardioSimFFRct Analysis Software on Coronary Artery Stenosis |
|
|
| Not yet recruiting | N/A | 325 | RoW | FFR and FFRCT | CCRF Inc., Beijing, China, Shengshi Technology, Co., Ltd, Hangzhou, China | Coronary Stenosis | 10/21 | 03/22 | | |
SIBLINT ISR, NCT04240444: Sirolimus-Coated Balloon Versus Paclitaxel-Coated Balloon for the Treatment of Coronary In-Stent Restenosis |
|
|
| Completed | N/A | 260 | RoW | drug-coated balloon Catheter | B. Braun Medical International Trading Company Ltd., CCRF Inc., Beijing, China | Coronary Artery Disease, In Stent Restenosis | 07/22 | 08/22 | | |
| Not yet recruiting | N/A | 220 | RoW | Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR), Paclitaxel-Eluting Balloon (Bingo) | CCRF Inc., Beijing, China | Percutaneous Coronary Intervention | 05/22 | 10/22 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
